Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Neil Horowitz, MD


Surgical Oncology

No Ratings Available - Why Not? Make an Appointment

Physician

  • Director, Clinical Research in Gynecologic Oncology
  • Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Clinical Interests

  • Cervical cancer
  • Endometrial cancer
  • Molecular imaging
  • Ovarian cancer
  • Vulvar cancer

Contact Information

  • Appointments617-632-2175 (new)
    617-632-3669 (follow-up)
  • Office Phone Number617-732-8843
  • Fax617-632-3479

Bio

Dr. Horowitz received his medical degree from Duke University School of Medicine in 1996. He subsequently completed his residency in Obstetrics and Gynecology at the University of Washington Medical Center in 2000, and his fellowship in Gynecologic Oncology at Barnes-Jewish Hospital in 2003. He joined the staff of Dana-farber Cancer Institute and Brigham and Women's Hospital in 2007, where he is a surgeon and clinical investigator in the Division of Gynecologic Oncology. Prior to joining DFCI he was an attending physician at Massachusetts General Hospital. His research focuses on complex gynecologic surgery, molecular imaging in gynecologic cancers, and development of novel therapies for gynecologic malignancies.

Board Certification:

  • Gynecologic Oncology, 2006
  • Obstetrics & Gynecology, 2005

Fellowship:

  • Barnes-Jewish Hospital, Gynecologic Oncology

Residency:

  • University of Washington Medical Center, Obstetrics & Gynecology

Medical School:

  • Duke University School of Medicine

Research

A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease. Lancet Oncol. 2021 Oct 05.
View in: PubMed

Challenges in the Treatment of Low-risk Gestational Trophoblastic Neoplasia. Rev Bras Ginecol Obstet. 2021 Jul; 43(7):503-506.
View in: PubMed

Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy. Clinics (Sao Paulo). 2021; 76:e2830.
View in: PubMed

Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. Int J Gynecol Cancer. 2021 Oct; 31(10):1341-1347.
View in: PubMed

Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right? Gynecol Oncol. 2021 Sep; 162(3):638-644.
View in: PubMed

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 Sep; 162(3):661-666.
View in: PubMed

Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel). 2021 Jun 28; 13(13).
View in: PubMed

Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 08; 22(8):1188-1198.
View in: PubMed

Loss of Selenoprotein Iodothyronine Deiodinase 3 Expression Correlates with Progression of Complete Hydatidiform Mole to Gestational Trophoblastic Neoplasia. Reprod Sci. 2021 Jun 15.
View in: PubMed

Treatment of hydatidiform mole using manual vacuum aspiration: technical and tactical aspects. Int J Gynecol Cancer. 2021 09; 31(9):1299-1300.
View in: PubMed

Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
View in: PubMed

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.
View in: PubMed

Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer. Ann Surg Oncol. 2021 Oct; 28(11):6705-6713.
View in: PubMed

Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586.
View in: PubMed

Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. Am J Reprod Immunol. 2021 07; 86(1):e13394.
View in: PubMed

Video Hysteroscopy in the Diagnosis of Molar Pregnancy in two Challenging Situations: Complete Mole with Normal hCG and Partial Mole with Early Gestational Age. J Minim Invasive Gynecol. 2021 Aug; 28(8):1448-1449.
View in: PubMed

Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. Best Pract Res Clin Obstet Gynaecol. 2021 Jul; 74:81-96.
View in: PubMed

When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia. Br J Cancer. 2021 03; 124(6):1033-1034.
View in: PubMed

Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease. Gynecol Oncol. 2021 02; 160(2):445-449.
View in: PubMed

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021 01 01; 81(1):158-173.
View in: PubMed

Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression. Am J Obstet Gynecol. 2021 04; 224(4):372.e1-372.e30.
View in: PubMed

Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. Gynecol Oncol. 2020 12; 159(3):751-757.
View in: PubMed

Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer. Gynecol Oncol. 2020 12; 159(3):687-691.
View in: PubMed

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
View in: PubMed

Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study. Curr Probl Cancer. 2021 02; 45(1):100622.
View in: PubMed

Female adnexal tumor of probable Wolffian Origin - A report of two cases at one institution. Gynecol Oncol Rep. 2020 Aug; 33:100612.
View in: PubMed

Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole. Clinics (Sao Paulo). 2020; 75:e1724.
View in: PubMed

Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer. Int J Gynecol Cancer. 2020 07; 30(7):1052-1057.
View in: PubMed

Correction: Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes. Mod Pathol. 2020 06; 33(6):1237.
View in: PubMed

How to optimize the management of gestational trophoblastic disease during the coronavirus disease era? Am J Obstet Gynecol. 2020 10; 223(4):604-605.
View in: PubMed

An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. Gynecol Oncol. 2020 08; 158(2):354-360.
View in: PubMed

EMA vs EMACO in the treatment of gestational trophoblastic neoplasia. Gynecol Oncol. 2020 07; 158(1):99-104.
View in: PubMed

Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. Gynecol Oncol. 2020 08; 158(2):452-459.
View in: PubMed

Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America. Int J Gynecol Cancer. 2020 09; 30(9):1366-1371.
View in: PubMed

Important insights for non-molar choriocarcinoma. BJOG. 2020 08; 127(9):1108.
View in: PubMed

Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer. Gynecol Oncol. 2020 06; 157(3):700-705.
View in: PubMed

Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2020 05; 157(2):372-378.
View in: PubMed

Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. Gynecol Oncol. 2020 03; 156(3):598-605.
View in: PubMed

Considering Changes in the Recommended Human Chorionic Gonadotropin Monitoring After Molar Evacuation. Obstet Gynecol. 2020 01; 135(1):9-11.
View in: PubMed

Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes. Mod Pathol. 2020 05; 33(5):880-892.
View in: PubMed

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020 07 15; 147(2):413-422.
View in: PubMed

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 12 01; 5(12):1731-1738.
View in: PubMed

State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia. J Natl Compr Canc Netw. 2019 11 01; 17(11):1396-1401.
View in: PubMed

Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough? Gynecol Oncol. 2019 10; 155(1):1-2.
View in: PubMed

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep. 2019 Aug; 29:118-122.
View in: PubMed

A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol. 2019 10; 221(4):326.e1-326.e7.
View in: PubMed

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240.
View in: PubMed

Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 2019 06; 153(3):471-478.
View in: PubMed

Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? Gynecol Oncol. 2019 05; 153(2):277-285.
View in: PubMed

Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. Int J Gynecol Cancer. 2019 03; 29(3):585-592.
View in: PubMed

A tumor board report of an 83-year-old woman with stage IB grade 3 endometrioid endometrial adenocarcinoma. Curr Probl Cancer. 2019 10; 43(5):443-449.
View in: PubMed

The association between progesterone receptor expression and survival in women with adult granulosa cell tumors. Gynecol Oncol. 2019 04; 153(1):74-79.
View in: PubMed

Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter? Gynecol Oncol. 2019 04; 153(1):63-67.
View in: PubMed

The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Gynecol Oncol. 2019 02; 152(2):426-433.
View in: PubMed

Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. J Pathol. 2018 11; 246(3):344-351.
View in: PubMed

Experience With the Use of an Online Community on Facebook for Brazilian Patients With Gestational Trophoblastic Disease: Netnography Study. J Med Internet Res. 2018 09 24; 20(9):e10897.
View in: PubMed

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
View in: PubMed

In Reply. Obstet Gynecol. 2018 07; 132(1):218.
View in: PubMed

Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? Gynecol Oncol. 2018 08; 150(2):233-238.
View in: PubMed

The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts. Gynecol Oncol. 2018 07; 150(1):67-72.
View in: PubMed

Gestational Trophoblastic Disease Electronic Consults: What Do Patients and Physicians Want to Know? Int J Gynecol Cancer. 2018 05; 28(4):824-828.
View in: PubMed

Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy. Obstet Gynecol. 2018 04; 131(4):652-659.
View in: PubMed

Extramammary Paget Disease of the Vulva: A Case Series Examining Treatment, Recurrence, and Malignant Transformation. Int J Gynecol Cancer. 2018 03; 28(3):632-638.
View in: PubMed

Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival. PLoS One. 2018; 13(2):e0193047.
View in: PubMed

Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma? Gynecol Oncol. 2018 02; 148(2):239-246.
View in: PubMed

Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecol Oncol. 2018 01; 148(1):5-11.
View in: PubMed

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol. 2018 02; 148(2):275-280.
View in: PubMed

Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol. 2018 01; 148(1):49-55.
View in: PubMed

A Randomized, Controlled, Multicenter Study of Technology-Based Weight Loss Interventions among Endometrial Cancer Survivors. Obesity (Silver Spring). 2017 11; 25 Suppl 2:S102-S108.
View in: PubMed

Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol. 2018 01; 148(1):161-167.
View in: PubMed

Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery. Gynecol Oncol. 2017 12; 147(3):612-616.
View in: PubMed

Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. Gynecol Oncol. 2017 07; 146(1):69-73.
View in: PubMed

Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol. 2017 Mar; 36(2):115-127.
View in: PubMed

Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol. 2017 Apr; 145(1):88-95.
View in: PubMed

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer. 2017 May 15; 123(6):985-993.
View in: PubMed

Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. Mod Pathol. 2017 03; 30(3):448-458.
View in: PubMed

Patient, treatment and discharge factors associated with hospital readmission within 30days after surgery for vulvar cancer. Gynecol Oncol. 2017 Jan; 144(1):136-139.
View in: PubMed

Management and outcome of cervical cancer diagnosed in pregnancy. Am J Obstet Gynecol. 2017 03; 216(3):276.e1-276.e6.
View in: PubMed

Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities. Gynecol Oncol. 2017 Jan; 144(1):208-214.
View in: PubMed

Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age. Gynecol Oncol. 2016 10; 143(1):73-76.
View in: PubMed

Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer. Int J Gynecol Cancer. 2016 07; 26(6):1033-40.
View in: PubMed

Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. Gynecol Oncol. 2016 08; 142(2):293-8.
View in: PubMed

Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prev Res (Phila). 2016 Sep; 9(9):713-20.
View in: PubMed

Gestational Trophoblastic Disease: Presentations from the XVIIIth World Congress on Gestational Trophoblastic Diseases. J Reprod Med. 2016 May-Jun; 61(5-6):185-6.
View in: PubMed

Maternal Near Miss According to World Health Organization Classification Among Women with a Hydatidiform Mole: Experience at the New England Trophoblastic Disease Center, 1994-2013. J Reprod Med. 2016 May-Jun; 61(5-6):210-4.
View in: PubMed

Timing of Referral to the New England Trophoblastic Disease Center: Does Referral with Molar Pregnancy Versus Postmolar Gestational Trophoblastic Neoplasia Affect Outcomes? J Reprod Med. 2016 May-Jun; 61(5-6):187-91.
View in: PubMed

Effect of race/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center. Am J Obstet Gynecol. 2016 09; 215(3):334.e1-6.
View in: PubMed

Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncol. 2016 Apr; 2(4):518-22.
View in: PubMed

Clinical Presentation of Complete Hydatidiform Mole and Partial Hydatidiform Mole at a Regional Trophoblastic Disease Center in the United States Over the Past 2 Decades. Int J Gynecol Cancer. 2016 Feb; 26(2):367-70.
View in: PubMed

The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy. Gynecol Oncol. 2016 Mar; 140(3):470-3.
View in: PubMed

Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1611.
View in: PubMed

Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1606-7.
View in: PubMed

Optimal management of low-risk gestational trophoblastic neoplasia. Expert Rev Anticancer Ther. 2015; 15(11):1293-304.
View in: PubMed

Reply to G.D. Aletti et al. J Clin Oncol. 2015 Oct 20; 33(30):3521-2.
View in: PubMed

Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer. Gynecol Oncol. 2015 Dec; 139(3):407-12.
View in: PubMed

Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23.
View in: PubMed

Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia? Gynecol Oncol. 2015 Jul; 138(1):46-9.
View in: PubMed

Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. Ann Surg Oncol. 2016 Jan; 23(1):178-85.
View in: PubMed

Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2015 May; 25(4):734-40.
View in: PubMed

Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2015 Jul; 138(1):50-4.
View in: PubMed

Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol. 2015 Jul; 138(1):201-6.
View in: PubMed

NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Jul 01; 121(13):2156-63.
View in: PubMed

Epithelioid trophoblastic tumor: A single institution case series at the New England Trophoblastic Disease Center. Gynecol Oncol. 2015 Jun; 137(3):456-61.
View in: PubMed

Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol. 2015 Mar; 39(3):287-93.
View in: PubMed

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015 Feb 26; 160(5):977-989.
View in: PubMed

Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015 Mar 10; 33(8):937-43.
View in: PubMed

Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva? Gynecol Oncol. 2015 Apr; 137(1):60-5.
View in: PubMed

Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer. Am J Obstet Gynecol. 2015 May; 212(5):600.e1-8.
View in: PubMed

Endometrial stromal sarcoma: a clinicopathologic study of 29 patients. J Reprod Med. 2014 Nov-Dec; 59(11-12):547-52.
View in: PubMed

Comparison of outcomes in patients with early-stage mucinous endometrial cancer and those with endometrioid endometrial cancer, with and without adjuvant therapy. J Reprod Med. 2014 Nov-Dec; 59(11-12):527-33.
View in: PubMed

Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014 Nov; 33(6):543-53.
View in: PubMed

Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer. Ann Surg Oncol. 2015 Apr; 22(4):1341-8.
View in: PubMed

Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7.
View in: PubMed

Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer. 2014 Dec 15; 120(24):3870-83.
View in: PubMed

Gestational trophoblastic disease: presentations from the XVIIth World Congress on Gestational Trophoblastic Diseases. J Reprod Med. 2014 May-Jun; 59(5-6):187.
View in: PubMed

What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014 Sep; 211(3):231.e1-9.
View in: PubMed

Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol. 2014 May; 133(2):216-20.
View in: PubMed

Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol. 2014 Mar; 132(3):760-6.
View in: PubMed

Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014 Feb; 132(2):280-6.
View in: PubMed

A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol. 2014 Jan; 132(1):55-60.
View in: PubMed

ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol. 2013 Nov; 10(11):822-7.
View in: PubMed

Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Sep; 23(7):1219-25.
View in: PubMed

Factors associated with an increased risk of recurrence in women with ovarian granulosa cell tumors. Gynecol Oncol. 2013 Nov; 131(2):321-4.
View in: PubMed

Prognostic determinants in patients with uterine and ovarian carcinosarcoma. J Reprod Med. 2013 Jul-Aug; 58(7-8):297-304.
View in: PubMed

Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. Gynecol Oncol. 2013 Sep; 130(3):487-92.
View in: PubMed

Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol. 2013 Aug; 130(2):312-6.
View in: PubMed

Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol. 2013 Apr; 129(1):69-73.
View in: PubMed

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
View in: PubMed

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
View in: PubMed

Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. Int J Gynecol Pathol. 2012 Jul; 31(4):337-43.
View in: PubMed

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012 Oct; 127(1):141-6.
View in: PubMed

ACR Appropriateness Criteria® pretreatment planning of invasive cancer of the cervix. J Am Coll Radiol. 2012 Jun; 9(6):395-402.
View in: PubMed

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012 Oct; 127(1):51-4.
View in: PubMed

A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. J Reprod Med. 2012 May-Jun; 57(5-6):211-8.
View in: PubMed

Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. Int J Gynecol Cancer. 2012 Mar; 22(3):417-24.
View in: PubMed

Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol. 2012 May; 125(2):376-80.
View in: PubMed

Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012 May; 125(2):362-6.
View in: PubMed

New biologic agents for the treatment of gynecologic cancers. Hematol Oncol Clin North Am. 2012 Feb; 26(1):133-56.
View in: PubMed

Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401.
View in: PubMed

Management of adnexal masses in pregnancy. Clin Obstet Gynecol. 2011 Dec; 54(4):519-27.
View in: PubMed

Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Jan; 124(1):53-8.
View in: PubMed

Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012 Mar; 19(3):959-65.
View in: PubMed

Surgical and oncologic outcomes in patients with breast cancer undergoing tattooing prior to neoadjuvant chemotherapy. J Clin Oncol. 2011 Sep 20; 29(27_suppl):100.
View in: PubMed

Characteristics of multifocal and multicentric breast cancers detetected by preoperative MRI. J Clin Oncol. 2011 Sep 20; 29(27_suppl):67.
View in: PubMed

Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun; 4(1):26-33.
View in: PubMed

ACR appropriateness Criteria® pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q. 2011 Jun; 27(2):139-45.
View in: PubMed

The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. J Clin Oncol. 2011 May 20; 29(15_suppl):5101.
View in: PubMed

Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):5072.
View in: PubMed

Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011 Jun 01; 121(3):477-81.
View in: PubMed

ACR appropriateness criteria© ovarian cancer screening. Ultrasound Q. 2010 Dec; 26(4):219-23.
View in: PubMed

Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol. 2010 Nov; 119(2):299-304.
View in: PubMed

When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol. 2010 Mar; 116(3):374-7.
View in: PubMed

Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer. BJOG. 2010 Jan; 117(1):32-8.
View in: PubMed

A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. Eur J Gynaecol Oncol. 2010; 31(3):284-7.
View in: PubMed

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
View in: PubMed

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
View in: PubMed

The epidemiology of ovarian granulosa cell tumors: a case-control study. Gynecol Oncol. 2009 Nov; 115(2):221-5.
View in: PubMed

Management of gestational trophoblastic neoplasia. Semin Oncol. 2009 Apr; 36(2):181-9.
View in: PubMed

Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J Reprod Med. 2009 Mar; 54(3):133-8.
View in: PubMed

Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9.
View in: PubMed

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
View in: PubMed

Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol. 2008 Nov; 111(2):289-97.
View in: PubMed

Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med. 2008 Aug; 53(8):589-94.
View in: PubMed

A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents. J Clin Oncol. 2008 May 20; 26(15_suppl):3544.
View in: PubMed

Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5590.
View in: PubMed

Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523.
View in: PubMed

PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging. 2008 Jan-Feb; 33(1):112-8.
View in: PubMed

Evaluating adnexal lesions: which need follow-up? J Am Coll Radiol. 2007 Oct; 4(10):725-9.
View in: PubMed

Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis. Gynecol Oncol. 2007 Nov; 107(2):344-9.
View in: PubMed

Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res. 2007 Aug 01; 67(15):7113-23.
View in: PubMed

Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol. 2007 Sep; 106(3):628-30.
View in: PubMed

Healing of vulvo-vaginal radionecrosis following revascularization. Gynecol Oncol. 2007 Jul; 106(1):262-4.
View in: PubMed

Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy. Gynecol Oncol. 2007 Jan; 104(1):70-6.
View in: PubMed

Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol. 2006 Nov; 103(2):684-7.
View in: PubMed

Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5081.
View in: PubMed

Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
View in: PubMed

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006 Oct; 103(1):212-8.
View in: PubMed

Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. N Engl J Med. 2006 Apr 13; 354(15):1615-25.
View in: PubMed

Advances in the surgical management of ovarian cancer. J Reprod Med. 2005 Jun; 50(6):454-66.
View in: PubMed

Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol. 2004 Dec; 95(3):546-51.
View in: PubMed

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol. 2004 Jul; 94(1):67-73.
View in: PubMed

Adequate staging for uterine cancer can be performed through Pfannenstiel incisions. Gynecol Oncol. 2003 Mar; 88(3):404-10.
View in: PubMed

Survival GYN/ONC. Washington University Obstetrics and Gynecology Survival Guide. Editors: Wright JD, Wyatt S, Lin T. 2003; 293-349.

Gynecologic Oncology. Washington University Hematology and Oncology Consult Manual. Editors: Chanter M, Pillot G, Lin T. 2003; 197-203.

Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol. 2002 Dec; 87(3):243-6.
View in: PubMed

Primary peritoneal carcinoma presenting as adenocarcinoma on a Pap smear. A case report. J Reprod Med. 2002 Nov; 47(11):933-5.
View in: PubMed

Placental site trophoblastic tumor presenting with a pneumothorax during pregnancy. Obstet Gynecol. 2002 Nov; 100(5 Pt 2):1141-4.
View in: PubMed

Microsatellite instability, hMLH1 methylation, and loss of mismatch repair in endometrial carcinoma and atypical hyperplasia. Gynecologic Oncology. 2002; 86(1):62-68.

Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecol Oncol. 2002 Jul; 86(1):62-8.
View in: PubMed

The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. Gynecol Oncol. 2002 Jul; 86(1):79-84.
View in: PubMed

Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients. Obstet Gynecol. 2002 May; 99(5 Pt 1):771-6.
View in: PubMed

Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol. 2002 Feb; 99(2):235-40.
View in: PubMed

Role of the ultrasonic surgical aspirator in gynecology. Obstet Gynecol Clin North Am. 2001 Dec; 28(4):775-90.
View in: PubMed

[Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center]. Harefuah. 2001 Apr; 140(4):289-93, 368.
View in: PubMed

Pretreatment scalene node biopsy in gynecologic malignancy: prudent or passé? Gynecol Oncol. 1999 Nov; 75(2):238-41.
View in: PubMed

Intraoperative ultrasound in the management of ovarian germ cell tumors. Journal Gynecol Tech. 1999; 5:91-94.

Calcifications in axillary lymph nodes caused by fat necrosis. AJR Am J Roentgenol. 1996 Sep; 167(3):627-8.
View in: PubMed

Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin. Immunopharmacology. 1995 Nov; 31(1):31-41.
View in: PubMed

Humoral immunity to herpes simplex viral-induced antigens in smokers. Cancer. 1976 Sep; 38(3):1155-62.
View in: PubMed

Location

Brigham and Women's Hospital
75 Francis Street
Boston, MA 02215
Get Directions

Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street
Newton, MA 02459
Get Directions

Top